SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------------------------------------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): March 29, 2000
Regeneron Pharmaceuticals, Inc.
----------------------------------------------------------------
(Exact name of registrant as specified in its charter)
New York 333-31764 133444607
--------------- ------------ ----------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.
incorporation)
777 Old Saw Mill River Rd, Tarrytown NY, 10591-6707
----------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
9143477000
----------------------------------------------------------------
(Registrant's telephone number, including area code)
Regeneron Pharmaceuticals, Inc.
Current Report on Form 8-K
Items 1-4. Not applicable.
Item 5. Other Events.
On March 29, 2000, the registrant entered into a purchase agreement
with Amgen Inc., Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner & Smith
Incorporated, Lehman Brothers Inc., J.P. Morgan Securities Inc. and FleetBoston
Robertson Stephens Inc., in connection with the issuance and sale by the
registrant of 2,600,000 shares of the registrant's common stock, par value $.001
per share (the "Common Stock"). Amgen Inc. granted the underwriters an option,
exercisable for 30 days after March 29, 2000, to purchase up to 390,000
additional shares of Common Stock, solely to cover over-allotments. The issuance
and sale of the Common Stock was consummated on April 4, 2000, with the total
gross proceeds to the registrant being approximately $73,502,000. Expenses
payable by the registrant in connection with the offering of the Common Stock
are estimated at approximately $550,000. The over-allotment option has not been
exercised.
Item 6. Not Applicable.
Item 7. Financial Statements and Exhibits.
The following exhibits are furnished in accordance with the provisions
of Item 601 of Regulation S-K:
Exhibit No. Description
----------- -----------
1.0 Purchase Agreement, dated March 29, 2000, among the
registrant, Amgen Inc., Merrill Lynch & Co., Merrill
Lynch, Pierce, Fenner & Smith Incorporated and
each of the other underwriters named therein.
Item 8. Not Applicable
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned's duly authorized signatory.
Dated: April 4, 2000
REGENERON PHARMACEUTICALS, INC.
By: /s/ Murray A. Goldberg
-----------------------------------------
Name: Murray A. Goldberg
Title: Vice President, Finance &
Administration, Chief Financial
Officer, Treasurer and
Assistant Secretary
3
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
1.0 Purchase Agreement, dated March 29, 2000, among the
registrant, Amgen Inc., Merrill Lynch & Co., Merrill
Lynch, Pierce, Fenner & Smith Incorporated and each
of the other underwriters named in Schedule A to the
Purchase Agreement.